the aid library

LIST OPTIONS

Filter

1757

Sort by:

Direction:

Download (635)

View PDF (3057)

Meningitis Outbreak Response in Sub-Saharan Africa

Christina Brandes-Barbier, Véronique Millot, Tomas Allen et al World Health Organization WHO (2014) C_WHO

WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics due to Neisseria meningitidis serogroup A (NmA) are... more

Download (602)

View PDF (2381)

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial

Jacob John, et al. The Lancet (2014)

The Lancet, Early Online Publication, 11 July 2014 doi:10.1016/S0140-6736(14)60934-X *Free registration is required to view this article

Download (784)

View PDF (876)

Kerala Antimicrobial Resistance Strategic Action Plan (KARSAP)

Department of Agriculture Development & Farmers Welfare; Health & Family Welfare, Government of Kerala (2018) C1

One health Response to AMR Containment. In a significant move for the public health sector, Kerala has become the first state in India to launch an action plan to combat the growing cases of antimicrobial immunity, arising primarily from irrational use of medicines and excessive antibiotics used in... more

Download (59)

View PDF (110)

Health Advisory for Elderly Population of India during COVID19 Pandemic

Ministery of Health and Family Welfare - Government of India (2020) C2

Elderly people are at a higher risk of COVID-19 infection due to their decreased immunity and body reserves, as well as multiple associated comorbidities like diabetes, hypertension, chronic kidney disease and chronic obstructive pulmonary disease. Also, course of disease tends to be more severe in ... more

Download (92)

View PDF (152)

COVID-19 natural immunity

World Health Organization WHO (2021) C_WHO

10 May 2021 This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020. This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considera... more

Download (48)

View PDF (84)

COVID-19 antibody testing and ‘immunity certification

Nuffield Council on Bioethics (2020) C1

Download (25)

View PDF (342)

WHO in ScienceEpisode #27 - Vaccines, variants & herd immunity

World Health Organization WHO (2021) C_WHO

As new variants emerge people are wondering if they should wait until a more efficacious vaccine is available or if they should go ahead and get vaccinated now? Answering your questions on COVID-19 vaccines and variants in this episode of Science in 5 is WHO's Dr Soumya Swaminathan.

Download (84)

View PDF (115)

How COVID-19 is changing the world. Vol.III

UN Department of Economic and Social Affairs (2021) C1

Since the release of the first volume in May 2020, the COVID-19 pandemic has continued to rage around the world. By mid-March, 2021, countries around the globe had reported over 123 million cases—a nearly five-fold increase since this report’s previous volume—and over 2.7 million deaths attrib... more

Download (29)

View PDF (610)

Comprehensive COVID-19 Slideset: Symptoms and Clinical Manifestations

Clinical Care Options (2021) CC

26 March 2021 Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.

Download (20)

View PDF (825)

COVID-19 vaccine side effects (Video)

World Health Organization WHO (2021) C_WHO

Vaccines are designed to give you immunity without the dangers of getting the disease. It’s common to experience some mild to moderate side effects when receiving vaccinations. This is because your immune system instructs your body to increase blood flow so more immune cells can circulate, and it ... more

Download (55)

View PDF (87)

Management of covid-19: a practical guideline formaternal and newborn health care providers inSub-Saharan Africa

B. N. Ezenwa, I. B. Fajolu, O. R. Akinajo, et al. The Journal of Maternal-Fetal & Neonatal Medicine (2020) CC

COVID-19 is a pandemic that is currently ravaging the world. Infection rate is steadily increasingin Sub-Saharan Africa. Pregnant women and their infants may suffer severe illnesses due to theirlower immunity. This guideline prepares and equips clinicians working in the maternal and new-born section... more

Download (47)

View PDF (452)

The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America

Argote P., Barhan E., Zukerman Daly S. et al. NPJ (2021) CC

Herd immunity by mass vaccination offers the potential to substantially limit the continuing spread of COVID-19, but high levels of vaccine hesitancy threaten this goal. In a cross-country analysis of vaccine hesitant respondents across Latin America in January 2021, we experimentally tested how fiv... more

Download (56)

View PDF (98)

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

Download (52)

View PDF (103)

Imunidade natural contra a COVID-19 Informe científico 10 de maio de 2021

Organização Mundial da Saúde (OMS) OPAS, OMS (2021) C_WHO

Natural immunity against COVID-19 Scientific report 10 May 2021

Download (16)

View PDF (500)

Dengue Explained in 5 Minutes

FreeMeEducation (2020) CC

There are currently 4 different serotypes of Dengue virus known to science. Each time someone get infected and recovers, the individual will be protected by a lifelong immunity from further infection against that specific serotype and that serotype only. Consequent infection from different serotype... more

Download (85)

View PDF (97)

Undernourished and Overlooked: A Global Nutrition Crisis in Adolescent Girls and Women.

UNICEF (2023) C_UNICEF

There has been important progress for the rights of adolescent girls and women in recent decades, yet millions still struggle to access the nutritious diets, essential nutrition services and nutrition and care practices they need to prevent malnutrition. Undernutrition, micronutrient deficiencies ... more

Download (94)

View PDF (102)

The Big Catch-Up: An Essential Immunization Recovery Plan for 2023 and Beyond

World Health Organisation (WHO) (2023) C_WHO

The backsliding of immunization coverage during the COVID-19 pandemic, combined with delayed catch-up efforts has resulted in a large and growing immunity gap. There is an urgent need to close this gap, and enable millions of missed children to be vaccinated. The Essential Immunization Recovery Plan... more

Download (54)

View PDF (55)

The urgency of now - Turning the tide against epidemic and pandemic infectious diseases

Coalition for Epidemic Preparedness Innovations (CEPI) Coalition for Epidemic Preparedness Innovations (CEPI) (2021) CC

CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to mobilise a portion of this $3.5 billion in 2021. We have already launched R&D programmes to initiate de... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (62)

View PDF (75)

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt... more